PATENT CLAIM ANALYSIS

Application Number: 16331579
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["514", "260100"]

Abstract:
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to fused bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.

Claim (Index 17):
The method according to  claim 16  wherein the cancer is selected from leukemias, myeloma, prostate cancer, lung cancer, breast cancer, pancreatic cancer, colon cancer, liver cancer, melanoma and glioblastoma.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 99.0
- Lexical Diversity: 1.34146
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15766887', '15537619', '15976037', '15537551', '15976223']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7652366109774172
- 35 USC 102 Novelty (BERT): 0.5291126381884865
- Combined Prediction Score: 0.7416242136985243
- Mean Citation Score: 294.28313799999995
- Max Citation Score: 308.84235
- Similarity Product: 198.94936544931832

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test